156 related articles for article (PubMed ID: 38646521)
61. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
62. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
[TBL] [Abstract][Full Text] [Related]
63. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.
Carlsten M; Björkström NK; Norell H; Bryceson Y; van Hall T; Baumann BC; Hanson M; Schedvins K; Kiessling R; Ljunggren HG; Malmberg KJ
Cancer Res; 2007 Feb; 67(3):1317-25. PubMed ID: 17283169
[TBL] [Abstract][Full Text] [Related]
64. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
[TBL] [Abstract][Full Text] [Related]
65. Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
Temming AR; de Taeye SW; de Graaf EL; de Neef LA; Dekkers G; Bruggeman CW; Koers J; Ligthart P; Nagelkerke SQ; Zimring JC; Kuijpers TW; Wuhrer M; Rispens T; Vidarsson G
J Immunol; 2019 Dec; 203(12):3126-3135. PubMed ID: 31748349
[TBL] [Abstract][Full Text] [Related]
66. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts.
Nielsen N; Pascal V; Fasth AE; Sundström Y; Galsgaard ED; Ahern D; Andersen M; Baslund B; Bartels EM; Bliddal H; Feldmann M; Malmström V; Berg L; Spee P; Söderström K
Immunology; 2014 Aug; 142(4):581-93. PubMed ID: 24673109
[TBL] [Abstract][Full Text] [Related]
67. Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C.
Borrego F; Lopez-Beltran A; Peña J; Solana R
Cell Immunol; 1994 Oct; 158(1):208-17. PubMed ID: 8087866
[TBL] [Abstract][Full Text] [Related]
68. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
69. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
Front Immunol; 2020; 11():1008. PubMed ID: 32528479
[TBL] [Abstract][Full Text] [Related]
70. Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts.
Costa D; Venè R; Benelli R; Romairone E; Scabini S; Catellani S; Rebesco B; Mastracci L; Grillo F; Minghelli S; Loiacono F; Zocchi MR; Poggi A
Front Immunol; 2018; 9():1150. PubMed ID: 29910806
[TBL] [Abstract][Full Text] [Related]
71. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.
Schmohl JU; Felices M; Todhunter D; Taras E; Miller JS; Vallera DA
Oncotarget; 2016 Nov; 7(45):73830-73844. PubMed ID: 27650544
[TBL] [Abstract][Full Text] [Related]
72. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
73. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
[TBL] [Abstract][Full Text] [Related]
74. Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.
Siernicka M; Winiarska M; Bajor M; Firczuk M; Muchowicz A; Bobrowicz M; Fauriat C; Golab J; Olive D; Zagozdzon R
Immunology; 2015 Sep; 146(1):173-83. PubMed ID: 26094816
[TBL] [Abstract][Full Text] [Related]
75. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
76. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
[TBL] [Abstract][Full Text] [Related]
77. FcγRIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcγRII (CD32).
Bhatnagar N; Ahmad F; Hong HS; Eberhard J; Lu IN; Ballmaier M; Schmidt RE; Jacobs R; Meyer-Olson D
Eur J Immunol; 2014 Nov; 44(11):3368-79. PubMed ID: 25100508
[TBL] [Abstract][Full Text] [Related]
78. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
Lagassé HAD; Ou J; Sauna ZE; Golding B
Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
[TBL] [Abstract][Full Text] [Related]
79. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
[TBL] [Abstract][Full Text] [Related]
80. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
